title: Increased annexin-V and decreased TNF-α serum levels in chronic-medicated patients with schizophrenia.
abstract: Schizophrenia (SZ) is a chronic severe mental disorder. Increased inflammatory processes have been shown in acute and chronic SZ. Apoptotic processes may alter the neuronal network and are involved in the pathogenesis of several neurodegenerative diseases, such as SZ. Annexin-V seems to have a role on inhibition of pro-inflammatory activities during apoptosis. Tumor necrosis factor (TNF-alpha) is a cytokine involved in systemic inflammation and is a member of a group of cytokines which stimulate acute phase reactions. A chronic immune activation in SZ has been shown. The aim of this study was to compare annexin-V and TNF-alpha serum levels in chronic medicated patients with SZ and healthy controls. Thirty-eight outpatients from the HCPA Schizophrenia Program and 38 healthy controls were enrolled to this study protocol. Annexin-V and TNF-alpha serum levels were measured with ELISA. Serum annexin-V levels were significantly higher in patients with SZ than in controls (p<0.001) and TNF-alpha significantly lower (p<0.001). The present result of increased annexin-V and decreased serum levels of TNF-alpha compared to controls may be a result of the stabilization phase of psychosis and a reduction in metabolic brain aggression. In this complex picture, increased levels of annexin-V and decreased levels of TNF-alpha in our sample would be explained by illness stability and chronic treatment. Our findings support the hypothesis of a state dependant process of inflammation in SZ. Further prospective studies to clarify the findings described in this paper are needed.
authors: Programa de Pós-Graduacão em Medicina, Ciências Médicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. le.petter@hotmail.com
authors: L P
authors: LP
authors: Francesconi
authors: K M
authors: KM
authors: Ceresér
authors: R
authors: R
authors: Mascarenhas
authors: L
authors: L
authors: Stertz
authors: C S
authors: CS
authors: Gama
authors: P
authors: P
authors: Belmonte-de-Abreu
mesh_terms: D000328:Adult; D017304:Annexin A5 / Q000097:blood* / Q000502:physiology; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D002908:Chronic Disease; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000097:blood* / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood* / Q000502:physiology; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
chemical_list: D017304:Annexin A5; D014150:Antipsychotic Agents; D014409:Tumor Necrosis Factor-alpha